Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Economic information and modeling report

Modeling overview

32 evidence topics · 31 sources

Summary

  • Descartes-08 price and revenue: the report holds no announced price for Descartes-08, and the company states that it has no products approved for sale and has not generated any product sales. An analyst page (2024) states that U.S. revenue for Descartes-08 is expected to reach an annual total of $201 mn by 2039 based on GlobalData's Expiry Model. A November 2026 company presentation describes a potential “$1B+ market opportunity for Descartes-08 in the US” and cites “Company internal projections, inclusive of opportunity to retreat patients”.
  • Comparator acquisition costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart ($15.79/mg; 2 or 3 vials per dose, weight based) as of September 30, 2025, and of $16,410.23 per vial ($16.28/mg) and $17,066.64 per syringe ($17.07/mg) of Vyvgart Hytrulo, 1 per dose, as of October 1, 2026; a Rystiggo list price of $3,155.37 per mL (AnalySource, December 2025), dosed in cycles of 1 weekly subcutaneous infusion for 6 weeks; a Zilbrysq list price printed as “$1,1164.21 per 23.0 mg syringe” (AnalySource, January 2026); an Imaavy list price of $12,480 per vial (2025); $6,523 per single-dose vial of Soliris, $5,870.70 per single-dose vial of the biosimilar Bkemv, and $4,566.00 per single dose of Epysqli (2025); and an Uplizna wholesale acquisition cost of $140,248.50 per dose (3 vials), given every six months after two loading doses (2025). Among 5,033 patients in the Optum database (mean body weight 86.6 kg), the annual cost of health-care-provider-administered gMG treatment was estimated at $223,272 to $648,960 depending on drug and body weight, up to $648,960 for patients weighing more than 80 kg. In Medicare drug claims for immune-mediated neurologic disorders, inebilizumab and eculizumab had the highest mean payment per claim in 2022 ($38 993.14).
  • ICER 2021 evaluation of eculizumab and efgartigimod: over a 2-year time horizon from a health system perspective, the incremental cost-effectiveness ratio for eculizumab, at an estimated annual cost of $653,100, was $5,210,000 per QALY/evLYG, and efgartigimod was analyzed at a placeholder price of $418,400. The ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million for efgartigimod, and in probabilistic sensitivity analyses neither drug reached cost-effectiveness at $150,000 per QALY/evLYG. Health benefit price benchmarks were $13,200 to $19,400 for eculizumab (97%-98% discount from the Federal Supply Schedule price) and $18,300 to $28,400 for efgartigimod, and 8.8% of the eligible population could be treated with efgartigimod at the placeholder price without passing the budget impact threshold.
  • Other cost-effectiveness analyses: a lifetime Markov model estimated $3,338,000/QALY gained for eculizumab and $1,987,000/QALY gained for efgartigimod compared with conventional therapy, $3,310,000 and $1,959,000 after indirect costs were applied in a modified societal perspective, with discounts of 93.01% and 88.34% needed for cost-effectiveness. A study that included 31 articles found considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. A network meta-analysis of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan using 2026 U.S. drug and administration costs found the lowest cost per improved outcome for efgartigimod IV across all QMG and MG-ADL thresholds. From the Canadian publicly funded healthcare system perspective, efgartigimod dominated chronic immunoglobulins (3.45 incremental QALYs and cost savings of $257,020 over a lifetime). From a UK NHS and Personal Social Services perspective, thymectomy plus prednisolone dominated prednisolone alone (0.52 QALYs gained and £13 014 saved per patient). The cost per MG-ADL improvement with IVIg was estimated at 7000-17,000 Japanese yen, lower than that for molecular targeted drugs.
  • CAR-T cell therapy costs: a single CAR T-cell infusion was described as approaching USD 500,000, and in a simple model the cumulative costs of systemic lupus erythematosus crossed that reference cost in approximately seven to eight years for very severe disease, 11 years for high disease activity, and 20 years for moderate disease activity. Among 8 patients with systemic lupus erythematosus followed for more than 2 years after CAR T cell therapy, annual direct healthcare costs in the German healthcare service fell from €29,672/year (US $34,353/year) to €3094/year ($3582/year). Among 271 commercially insured patients treated for B-cell lymphoma, median total costs were $608 100, the median cost of CAR-T products was $402 500, and 8.5% had total costs exceeding $1 million. Among 508 patients in a health plan claims database, mean total 30-day costs after infusion were $643,902 in the outpatient cohort and $691,771 in the inpatient cohort. The estimated total cost of care associated with CAR T-cell administration was $454 611 in academic inpatient hospitals and $421 624 in nonacademic specialty oncology networks. Costs of cilta-cel therapy excluding acquisition totaled US$160,933 over 12 months, including $18,268 in pre-infusion costs (apheresis, bridging therapy, and conditioning therapy), against a 2022 wholesale acquisition cost of $465,000. ICER's 2021 multiple myeloma assessment estimated $319,000 per QALY for ide-cel at its wholesale acquisition cost of $419,500 and a health benefit price benchmark of $192,000 to $265,000 per dose.
  • CAR-T payment: across 391 Medicare CAR-T claims, 79% were administered in the inpatient setting, and the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. An inpatient case is paid through the claim's DRG, with the product included in a single payment for the stay, and a solely outpatient case is paid under the Outpatient Prospective Payment System at Average Sales Price plus 6%. In the FY 2027 final rule, CMS estimated average costs of $64,963 for clinical trial cases and $410,125 for nonclinical trial cases assigned to MS-DRG 018, and a commenter stated that the MS-DRG 018 base payment rate remains insufficient to cover the costs of CAR T-cell and other cellular immunotherapies.
  • Eligible population inputs: ICER's 2021 budget impact model used 46,870 U.S. patients with gMG, assumed 100% diagnosis and 20% annual initiation (9,374 additional patients per year), and set initial market shares of 2.27% for eculizumab and 97.73% for conventional therapies. A November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020. Treatment-refractory gMG prevalence estimates range from 5% to 15%; among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first (n = 7986) and fifth (n = 3340) treatment episodes.

Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG

Break-even analysis of a CAR-T cell therapy reference price against cumulative costs of systemic lupus erythematosus: United States

“A single infusion of chimeric antigen receptor (CAR) T-cell therapy (CTCT) is currently expensive, approaching USD 500,000, but the lifetime costs of SLE, including medications, hospitalizations, travel, mental health effects, and lost income, may surpass this figure within years to over a decade, depending on disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Costs for patients with very severe SLE cross the reference CTCT cost in approximately seven to eight years. Estimated breakeven timelines vary by severity level as follows: patients with high disease activity reach breakeven in approximately 11 years, and those with moderate disease activity in approximately 20 years. For mild or inactive SLE, CTCT is not cost-effective at current prices within a clinically meaningful timeframe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Looking forward, emerging strategies, such as off-the-shelf (allogeneic) CTCT, RNA delivery, or hospital-based manufacturing, could reduce CAR T manufacturing costs to USD 80,000 or below [22-24].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We used a simple model to compare the financial burden of living with SLE to the cost of a single dose of CTCT. Our model did not account for all factors, such as inflation, regional cost differences, or changes in insurance coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Total cost of care around commercial CAR-T cell therapy for B-cell lymphoma: U.S. commercial claims, 2018 to 2021

Medicare costs and reimbursement of CAR-T cell therapy by setting of care: fee-for-service claims, 2021 to 2022

“Among the total 391 CAR T claims assessed, most of the CAR T therapies were administered in the inpatient setting (79%) compared to outpatient (21%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“CAR T therapy in the inpatient setting received an average Medicare cost of US$498,723” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“while the average Medicare cost for outpatient CAR T claims was $414,393” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Despite the higher post-period cost, when looking at the CAR T procedure and pre- and post-periods as a single episode, beneficiaries receiving outpatient CAR T had less cost for the total episode of care ($587,908 vs. $529,188).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When an OP case is admitted into the same hospital within 72 h, the CAR T infusion will be designated by CMS as IP and paid based on the claim's DRG (diagnosis-related grouping). DRG payment rates are set by CMS' Inpatient Prospective Payment System. In IP claims, the CAR T product is not reimbursed individually but rather it is part of a single payment for the entire IP stay. When a case is solely OP (without any IP admission within 72 h), the CAR T product is paid under CMS' Outpatient Prospective Payment System and is set to Average Sales Price (ASP) plus 6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Company slide: AChR antibody-positive share and basis of the U.S. market estimate

Item on the slideQuoted text
Share of the estimated U.S. patient population with AChR antibodies“~85%”
Reference cited for that share“Lazaridis et al., 2020”
Basis stated for the U.S. potential addressable market“Company internal projections, inclusive of opportunity to retreat patients”

Vyvgart Hytrulo wholesale acquisition cost per vial and prefilled syringe, October 2026

Product and presentationWholesale acquisition costPrice per mgUnits per dose
VYVGART Hytrulo single-dose vial, 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase“$16,410.23”“$16.28/mg”“1 vial per dose”
VYVGART Hytrulo single-dose prefilled syringe, 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase“$17,066.64”“$17.07/mg”“1 prefill syringe per dose”